Exploration of novel fusion gene of prostate cancer in Japan

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09383
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Jikei University School of Medicine
• Principal Investigator: Kimura Takahiro 東京慈恵会医科大学, 医学部, 教授 (00307430)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 前立腺癌 / 融合遺伝子

Outline of Final Research Achievements

The expression of the ELOVL5:LRRC1 gene fusion, identified through next-generation sequencing analysis of a prostate cancer mouse subcutaneous transplantation model established from prostate cancer patients, was investigated using prostate cancer cells and clinical specimens. The expression of the ELOVL5:LRRC1 gene fusion was confirmed in the human prostate cancer subcutaneous transplantation models (JDCaP and JDCaP-CR) and the human prostate cancer cell line LNCaP, but it was not detected in the human prostate cancer cell line PC3. Furthermore, analysis of the ELOVL5:LRRC1 gene fusion in clinical specimens using the FISH method confirmed its presence in three biopsy samples of metastatic prostate cancer.

Free Research Field

泌尿器科学

Academic Significance and Societal Importance of the Research Achievements

当科で前立腺癌患者の転移組織より樹立した内分泌感受性前立腺癌マウス皮下移植モデルJDCaPおよびその去勢抵抗性モデルであるJDCaP-CRの次世代シークエンス解析により同定された遺伝子融合遺伝子ELOVL5:LRRC1を前立腺癌細胞株だけではなく臨床検体においても確認することができた。本研究では、ELOVL5:LRRC1遺伝子融合の前立腺癌における発癌および癌進展への作用の解明には至らなかったが、日本人症例で確認できたことにより、今後の新たなバイオマーカーや治療標的としての可能性を示すことができた。